CD19 B-cell recovery over time in patients who achieved a complete response (n = 27) in the dose-escalation and dose-expansion cohorts.
Note: The proportion of patients with low (<70 cells/µL) or normal (≥70 cells/µL) CD19+ B cell counts at specified timepoints during treatment and follow-up visits are indicated. C1D1-PRE, C2D1, C3D1 and C5D1 represent timepoints before treatment dosing. C1D1 after polatuzumab vedotin represents the timepoint 30 minutes after polatuzumab vedotin infusion. C1D1 after mosunetuzumab represents the timepoint 2 hours after subsequent mosunetuzumab treatment. The number of patients observed at each time point is depicted at the bottom of each bar. Months at follow-up were calculated from the end of initial treatment ±45 days. The number of B-cell count assessments varied for each patient across the study period.
